Earth is the solitary planet in the universe known to possess life, and there are more than 7,000 known rare diseases that affect just about 400 million individuals globally. 80% of these diseases mainly have genetic origins and 50% affect children. Collectively, individuals living with a rare disease represent one of the large-scale underserved patient populations in the world, with only 5% of known rare diseases having single or multiple approved therapies.

At IKRIS Pharma, we believe that individuals living with a rare disease, along with the unspecified number of family members and caregivers who assist them, deserve no doubt much more. For several years, we've provided critical treatment options for patients with rare diseases. 

We’re leading the way in an effort to deliver an advanced and new generation of breakthrough therapies across different modalities i.e. small molecule, large molecule, or monoclonal antibodies, and gene therapies: to potentially unseal the promise of science for zillions with rare diseases for whom the present standard of care falls short. 

Why IKRIS for Rare Disease Medications?
Universal health coverage can only be attained when there is more affordable access to genuine, safe, effective, and quality medications and health products. Nations face a range of obstacles to achieve this, including a hike in prices for new therapies; shortages of essential medicines, especially for rare diseases, and the emerging problem of substandard and counterfeit or falsified drugs entering the global supply chain.

Counterfeit drugs/medicinal products have been defined as drugs deliberately and fraudulently developed and/or mislabeled concerning identity and/or source to turn it appear to be an authentic or genuine product. 

Counterfeit medicinal products include drugs that contain no active ingredient (API), an inappropriate amount of active ingredient, an inferior-quality active ingredient, a wrong active ingredient, contaminants, or repackaged expired products. Certain counterfeit drugs may even be inappropriately formulated and produced in substandard conditions. 

Counterfeiting can apply to both brand names and their less expensive generic counterparts. In fact, generic medications are sometimes confused with counterfeit medicines, which may pose an obstacle to the widespread application and acceptance of generic medicines.

For years, zillions of counterfeit drugs that have made their way into trusted healthcare centers, pharmacies, and subsequently to patients’ medication cabinets have been on the rise. Just think of the scenario in which a particular patient takes medicine for a life-threatening illness, only to become aware later that the doses of that medication contain no Active Pharmaceutical Ingredients. It is believed that this affliction has arisen with thousands of individuals at the global level and continues to happen. The emerging issue of counterfeit drugs is a concern not only for the specific patient but also for health specialists and pharmaceutical firms.

High-demand, expensive medications such as numerous chemotherapeutic medicines, erectile dysfunction drugs, vaccines, weight loss aids, hormones, analgesics, steroids, antibiotics, antihistamines, antivirals, and anti-anxiety medicines are common counterfeiting targets. Added to this, there are certainly zillions of other challenges to ensuring that medications are not only available but are used in appropriate ways. 

With an impeccable objective of making safe, quality, effective medicine available at affordable prices to all, IKRIS Pharma was launched in 2014. Superior access to medication is relevant to every individual because, after all, we’re all patients at some point. As of now, we have assisted countless patients under Named Patient Import. We allow/provide validated and customized solutions for cold chain products, including vaccines. We have exported Indian Generic medicine to over 100+ countries, including the UK, Brazil, China, Romania, Italy, Russia, Poland, Australia, Latvia, South Africa, Mexico, etc.

In recent years, Ikris Pharma has successfully constructed an efficient network and is the only company to have a pan-India presence with GDP and ISO certification under WHO Guidelines.

We Specialize In:

• Access to Indian Generic Medicines
• Providing access to licensed and unlicensed medicines through Named Patient Import Services
• RLD Supply / Comparator Sourcing from India, Europe, USA, Japan, Australia, and more
• Contract Manufacturing / Private Label Manufacturing
• Validated Cold Chain Supplies

We have established our own operations under the IKRIS Pharma Network in Belgium and Bulgaria (Europe), which serve as our sourcing office
IKRIS Pharma operates under EU-compliant SOPs and holds an EU Good Distribution Practice (GDP) certificate, issued by the Belgian Federal Agency for Medicines and Health Products.